Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation

by Valesca P. Retèl, Lotte M. G. Steuten, Marnix H. Geukes Foppen, Janne C. Mewes, Melanie A. Lindenberg, John B. A. G. Haanen, Wim H. van Harten
Published 2018-09-01

Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up

by Joost H van den Berg, Raquel Gomez-Eerland, Samira Michels, Maaike van Zon, Renate de Boer, Noor A M Bakker, Marit M van Buuren, Henk Mallo, Matthias Karger, Joris A van der Hage, Loes M Pronk, Marnix H Geukes Foppen, Bastiaan Nuijen, Ton N Schumacher
Published 2020-07-01